Member Info for TrickyEFC

Dealer sad ain't it.

Smallest book I've seen, given that he's been about for 5 mins.

😂😂😂😂

Conversation and discussion musk.

Imagine going the match and not speaking or texting a word about it to anyone They call such type of things an 'interest' people talk to each other. Hell am even talking to a massive helmet right now.

11-Apr-25 15:07:24 0.837 3,583,632 Unknown* 29.99k

He said the action around 3.30 on friday indicated a rather large buy order

£30k at 0.837.

Well spotted and called Mr Wick.

That it will allow they to open it down tomorrow when it really won't be down.

someone is playing silly buggers.

either mms or skin flint day traders smashing free trade apps.

normal people would not buy and sell such small amounts.

the ut is deffo mms taking the ****

In the works of kammy what's happening jeff

Blow scarlet blow.

Ya just blew us 2.5%

all these ****y trades yet again.

free apps and penny day traders

They?

An ambush of tigers?? Multiple tigers 😂😂

Scarlet bet you blow better

-Apr-25 08:34:48 0.845 1,182,485 Unknown* 9,992

Paying 0.845 now 💪

14-Apr-25 08:14:48 0.80 1,249,000 Unknown* 9,992 O

14-Apr-25 08:14:10 0.795 1,256,478 Unknown* 9,989

Still getting hammered with some decent orders

And someone hopefully buys em and it goes higher

Someone is selling out big

John wick I applaud your eye for detail.

we only had 3 big delayed sells through the day and the last large trade below was a buy. Could it be that

11-Apr-25 15:00:00 0.795 942,894 Unknown* 7,496

Could be that it took just £7k to cause the lift.

AWKN-001 is an investigational, novel combination therapy consisting of an N-methyl-D-aspartate ("NMDA") receptor-modulating drug (ketamine) delivered intravenously ("IV") in combination with copywritten relapse prevention cognitive behavioural therapy ("CBT") for the treatment of severe AUD in the UK and potentially the EU.

Phase 2 results demonstrated a 50% reduction in heavy drinking days in the 6 months post treatment versus the placebo. The phase 2 results also demonstrated an on average 86% abstinence rate in the 6 months post treatment versus 2% abstinence pre-trial.

Current status: AWKN-001 is in a Phase 3 clinical trial in the UK across 9 NHS Trusts. The Phase 3 trial is co-funded by a partnership between the UK's Medical Research Council (the "MRC"), the National Institute for Health and Care Research (the "NIHR"), and Awakn. Awakn's costs are capped at £800,000. The trial is managed the University of Exeter Clinical Trials Unit

Posting this again because if we end up wrighting off 703million of the remaining headroom for the future prospects of warrant being converted we seem in a better position.

SVNS currently have 2.3b shares in issue valued at £3.73million.

awakn take over for consideration of 2.01b shares.

based on current price of 0.1625 values company at £7.1million.

Now dare I say the exciting part, the fund raise. SVNS are looking to have authority to issue up to 7.5b shares.

So if we remove the current shares and the consideration shares that leaves room for 3,125,621,408 shares for equity.

3.12b x 0.075p £2.3million

x 0.10p = £3.125 million

x0.15p = ££4.6million

x0.20p = £6.2 million

Well well well. The resolution will allow the company sufficient head room to facilitate the take over, the working capital for at least 12 months and here's the the juicy bit it will also allow the headroom for the potential conversion of new warrants of which there will be 703million.

Purcel exercise price is 0.814 pence.

He will provide positive news before the resumption of trading.

PharmaVentures engagement

The engagement of PharmaVentures, by the Company, is structured in two phases:

· Phase 1 - a review of comparable transaction valuations and market sizing exercise in relation to target clinical use of AWKN-001 and AWKN-002; and

· Phase 2 - transaction advisory support to guide the commercialisation strategy for AWKN-001.

Market opportunity for AWKN-001 and AWKN-002

The first phase of the engagement - the review of comparable transaction valuations and market sizing exercise in relation to target clinical use of AWKN-001 and AWKN-002 - has now been completed. The analysis by PharmaVentures shows the following:

· AWKN-001 is a novel investigational combination therapy for the treatment of severe AUD. It is targeting full mixed marketing authorisation in the UK and EU, with expected regulatory protection to include eight years of data exclusivity in the EU and ten years of concurrent market exclusivity in both regions

Based on a market analysis by PharmaVentures, comparable transactions for late-stage UK/EU-focused assets in the substance use disorder space, typically achieve a total deal value of approximately £60 million, in upfront and commercial milestone payments, plus additional future material royalties on net sales[2].

· AWKN-002 is a proprietary, investigational, patent-pending sublingual or buccal esketamine formulation designed for use alongside manualised behavioural therapy in patients with moderate to severe AUD. It is currently in Phase 2b planning in the US and is expected to follow the FDA's 505(b)(2) regulatory pathway.

According to PharmaVentures' market analysis, subject to the successful completion of the planned Phase 2b trial and based on similar transactions for mid-stage assets, comparable assets typically achieve a total deal value of approximately £150 million, in upfront and commercial milestone payments, plus additional future material royalties on net sales2.

Adrian Dawkes, Managing Director of PharmaVentures, commented: "Based on market comparables and recent transactions in the substance use disorder space, our analysis highlights the significant commercial potential of these two clinical-stage programmes with potential value based on comparable assets of more than £200 million as well as future material royalties on net sales. Combined, AWKN-001 and AWKN-002 represent a significant commercial opportunity with potential for significant licensing deals with substantial future royalty streams."